US Stock MarketDetailed Quotes
XLO Xilio Therapeutics
- 1.280
- +0.342+36.46%
Close Dec 20 16:00 ET
- 1.240
- -0.040-3.13%
Post 19:59 ET
56.27MMarket Cap-0.83P/E (TTM)
1.280High0.836Low6.83MVolume1.060Open0.938Pre Close7.53MTurnover31.28%Turnover RatioLossP/E (Static)43.96MShares1.93052wk High2.68P/B27.96MFloat Cap0.50052wk Low--Dividend TTM21.84MShs Float27.950Historical High--Div YieldTTM47.29%Amplitude0.490Historical Low1.101Avg Price1Lot Size
Xilio Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -2.27%-13.67M | 220.39%19.95M | 58.41%-10.5M | 9.38%-68.62M | 26.32%-13.43M | 32.85%-13.37M | 1.09%-16.57M | -21.19%-25.25M | 6.23%-75.72M | -6.18%-18.22M |
| Net income from continuing operations | 16.29%-14.02M | 28.05%-13.93M | 24.04%-17.2M | 13.40%-76.4M | 21.41%-17.66M | 15.37%-16.75M | 21.36%-19.36M | -6.06%-22.65M | -16.39%-88.22M | -14.03%-22.47M |
| Operating gains losses | ---- | ---- | ---- | 200.00%3K | --0 | --1K | ---- | ---- | -99.55%1K | --0 |
| Depreciation and amortization | -17.17%381K | -9.55%445K | -11.22%443K | 2.87%1.9M | -8.18%449K | -2.75%460K | 10.56%492K | 13.41%499K | 23.22%1.85M | 24.11%489K |
| Other non cash items | --0 | --0 | -103.23%-1K | -29.60%157K | -72.88%16K | -60.34%23K | 64.15%87K | -41.51%31K | 28.90%223K | 13.46%59K |
| Change In working capital | -255.61%-1.61M | 7,880.50%31.92M | 189.87%4.43M | -182.73%-1.66M | -2.50%1.83M | 141.00%1.03M | -91.40%400K | -145.76%-4.93M | 116.98%2M | 10,344.44%1.88M |
| -Change in receivables | ---- | ---- | ---30M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| -Change in prepaid assets | 160.56%1.01M | 223.68%2.15M | -538.92%-1.78M | 100.00%688K | 236.85%1.29M | -491.08%-1.67M | 27.26%663K | 20.83%406K | 110.97%344K | -303.69%-939K |
| -Change in payables and accrued expense | -107.98%-225K | 1,661.38%2.26M | 46.44%-2.8M | -191.21%-1.89M | -77.27%665K | 199.12%2.82M | -103.42%-145K | -132.58%-5.23M | 124.54%2.07M | 936.00%2.93M |
| -Change in other current assets | 17.09%137K | 16.81%132K | 17.59%127K | 17.65%460K | 18.45%122K | 17.00%117K | 17.71%113K | 17.39%108K | 17.77%391K | 17.05%103K |
| -Change in other current liabilities | -13.62%-267K | -13.85%-263K | -14.55%-244K | -14.61%-918K | -13.81%-239K | -14.63%-235K | -14.93%-231K | -15.14%-213K | -42.02%-801K | -16.02%-210K |
| -Change in other working capital | ---2.26M | ---2.36M | --39.12M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -2.27%-13.67M | 220.39%19.95M | 58.41%-10.5M | 9.38%-68.62M | 26.32%-13.43M | 32.85%-13.37M | 1.09%-16.57M | -21.19%-25.25M | 6.23%-75.72M | -6.18%-18.22M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -9K | 93.35%-21K | 0 | 73.97%-486K | 0 | 0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K |
| Net PPE purchase and sale | ---9K | 93.35%-21K | --0 | 73.97%-486K | --0 | --0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---9K | 93.35%-21K | --0 | 73.97%-486K | --0 | --0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 99.87%-3K | 2,120.46%20.04M | 156.52%954K | -9,392.75%-6.55M | -7,680.95%-1.63M | -10,063.64%-2.24M | -4,623.81%-992K | -33,660.00%-1.69M | -100.03%-69K | -100.02%-21K |
| Net issuance payments of debt | 99.69%-7K | 98.14%-21K | -98.70%-3.35M | -7,843.53%-6.75M | -7,938.10%-1.69M | -10,100.00%-2.24M | -5,290.48%-1.13M | -7,938.10%-1.69M | 22.73%-85K | 4.55%-21K |
| Net common stock issuance | --0 | --2.52M | --4.31M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -50.00%4K | ---- | ---- | 1,162.50%202K | --54K | --8K | ---- | ---- | -94.35%16K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 99.87%-3K | 2,120.46%20.04M | 156.52%954K | -9,392.75%-6.55M | -7,680.95%-1.63M | -10,063.64%-2.24M | -4,623.81%-992K | -33,660.00%-1.69M | -100.03%-69K | -100.02%-21K |
| Net cash flow | ||||||||||
| Beginning cash position | -0.31%76.72M | -61.26%36.74M | -62.04%46.29M | -38.91%121.95M | -56.40%61.35M | -52.19%76.96M | -46.87%94.84M | -38.91%121.95M | 860.15%199.61M | 38.87%140.7M |
| Current changes in cash | 12.31%-13.68M | 323.55%39.98M | 64.78%-9.55M | 2.58%-75.66M | 19.69%-15.06M | 22.99%-15.61M | -1.90%-17.88M | -28.51%-27.11M | -143.43%-77.66M | -119.08%-18.75M |
| End cash Position | 2.74%63.03M | -0.31%76.72M | -61.26%36.74M | -62.04%46.29M | -62.04%46.29M | -56.40%61.35M | -52.19%76.96M | -46.87%94.84M | -38.91%121.95M | -38.91%121.95M |
| Free cash flow | -2.33%-13.68M | 218.01%19.93M | 58.69%-10.5M | 10.93%-69.11M | 28.32%-13.43M | 33.95%-13.37M | 3.63%-16.89M | -20.54%-25.42M | 5.21%-77.59M | -6.80%-18.73M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data
